A CONTROLLED ONE‐YEAR STUDY OF PIPOTIAZINE PALMITATE AND FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIC SYNDROMES: <i>Evaluation of results at 6 and 12 months' trial</i>

Self Cite

A group of patients, initially 67 individuals, with chronic schizophrenia were studied on repeated occasions during 1 year and followed up after 3 years. The patients were given depot neuroleptics, either fluphenazine decanoate or pipotiazine palmitate, at intervals of 1 month. The symptom scores from three rating scales were subjected to factor analysis. Four factors were found to explain the variance satisfactorily: one comprising psychopathological symptoms specific for schizophrenia, one relating to contact disturbances, one psychomotor activity and one representing neurotic symptoms. Analysis of these factors revealed certain differences between the treatment groups over time and demonstrated the effect of combination of psychotherapy and neuroleptic drugs in a subgroup of patients. This type of analysis of treatment results might contribute to improving our knowledge of rehabilitation of schizophrenic patients and help us to draw up giudelines for selection of suitable measures.

Section: Discussionmentioning

confidence: 99%

How schizophrenic patients change during 3 years' treatment with depot neuroleptics

Dencker

Frankenberg

Lepp

et al. 1978

Self Cite

“…I would like to discuss two studies, both running for one year, comparing two depot neuroleptic drugs, fluphenazine decanoate and pipothiazine palmitate in one case (Dencker et al (1973)) and clopenthixol decanoate and flupenthixol palmitate in the other (Dencker et al (1980b)). The following two features were characteristic for the latter study:…”

Section: Optimal Symptom Suppressionmentioning

confidence: 99%

The need for long‐term neuroleptic treatment in schizophrenia

Dencker¹

1981

Self Cite

The need for long-term neuroleptic treatment in nuclear schizophrenia depends on several factors, including the type of chronic schizophrenia, the phase of the disease, and the patient's total social situation. A neuroleptic drug withdrawal study demonstrated a need for further neuroleptic treatment for survival in the community even when the most symptom-free and socially best adapted chronic schizophrenics were considered. Prevention of relapse can apparently be achieved with lower neuroleptic doses than those necessary for optimal symptom suppression. Moreover, the patient's evaluation of his total social situation, including some quality-of-life aspects, must be considered as well as measures to avoid the patient becoming a burden on his family and friends. Neuroleptic treatment in adequate antipsychotic doses usually means a risk of early, immediate and possibly late side effects. In striking a balance between benefit and risk it seems preferable to keep the benefit strategy, which means that the main point will be to monitor neuroleptic and antiparkinsonian drugs with regard to optimal symptom suppression not accepting any possible late side effects as a guideline. This presentation will focus upon three questions concerning the long-term neuroleptic treatment of nuclear schizophrenia:1. which type of schizophrenia do we treat? 2. does the schizophrenic need long-term neuroleptic treatment? 3. if so, which is the best drug, and what is the ideal dose and most suitable form of administration for a. optimal symptom suppression, and b. prevention of relapse. SCHIZOPHRENIC SUBGROUPSThe diagnostic criteria for chronic schizophrenia have already been discussed by Wistedt (1980) and I agree with him on all points. The schizophrenic population varies however in several respects. These variable factors include the need for continuous hospital care and alternative support, the need for psychotropic drugs, psychotherapy and social training programmes, the quality-of-life and so on. I have not been able to

“…In 1973 we reported the results of a 1-year controlled study comparing fluphenazine decanoate (FD) and pipotiazine palmitate (PP) (Dencker et al (1973a)). The present report presents the findings in the same group of patients after a further 2 years of treatment.…”

mentioning

confidence: 99%

Three years' maintenance neuroleptic treatment in schizophrenia – before and beyond

Dencker

Frankenberg

Lepp

et al. 1978

Self Cite

A group of patients with schizophrenia, initially 67 patients, was studied over a period of 3 years. After three years 36 out of 67 patients were still on the same depot neuroleptic. The main aim was to describe and compare maintenance neuroleptic therapy using two depot neuroleptics, fluphenazine decanoate and pipotiazine palmitate, given monthly. Before the outpatient care the patients had participated in the department's comprehensive hospital treatment including depot neuroleptic medication. After a 1-year clinical trial with frequent assessments of the patients, significant symptom reductions were found on all rating scales. During the last 2 years of the study only drug therapy was given. Improvement concerning social function in the community and work level as well as the low-rated psychopathology noted at the start of study also persisted at the 3-year follow-up. The side effects were low in frequency and quality. These results show the clinical value of long-term maintenance treatment with depot neuroleptics. The results also confirm that the favourable effects of the hospital treatment demonstrated before the start of the clinical trial could be maintained. The possibilities of further improving aftercare and outpatient treatment beyond medication alone are discussed.